Why Join Intellia?
Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.
We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.
How You Will Achieve More with Intellia:
Intellia Therapeutics, a pioneer in gene editing, is preparing to launch its first gene editing therapies, with a focus on groundbreaking treatments for rare and serious diseases, including hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR). We are seeking an experienced Senior Director of Market Access Strategy and Value Communication to lead our strategic and tactical efforts in demonstrating the value of, and facilitating the adoption of, these therapies. This role is critical to ensuring successful product launches, fostering market access, site readiness, and building compelling narratives that resonate with diverse stakeholders, from healthcare providers, channel partners, and payers to patients and caregivers. This role will primarily serve as the access launch lead for HAE, with secondary responsibilities for future launches such as ATTR-PN & ATTR-CN.
Responsibilities:
- Access & Value Strategy Development: Lead the creation and execution of comprehensive market access & value strategies that clearly communicate the impact and benefits of Intellia’s gene editing therapies in HAE, ATTR, and related indications. Develop and refine strategies that align with our commercial goals and resonate in global markets.
- Stakeholder Communication: Develop clear and persuasive communication plans that effectively convey the differentiated value proposition of our therapies. Partner with cross-functional teams, including market access, HEOR, marketing, medical affairs, and corporate communications, to craft narratives that address the needs and interests of clinicians, payers, channel partners, and patient advocacy groups. Identifies evidence enhancements & gaps to inform future research objectives to bolster the value proposition and to support product positioning and aligned access goals.
- Launch & Site Readiness: Develop and refine launch plans and lead execution of market access strategies, marketing initiatives and corresponding materials/ innovative tactics to ensure launch readiness across all access channels to secure access for providers and patients.
- Market development: Work to establish reimbursement pathways for first-in-class gene therapies across access stakeholders including payer pre-launch engagement plans and site readiness preparation, including supporting marketing programs and communication materials.
- Market Insights & Competitive Intelligence: Leverage insights from the HAE and ATTR access & payer landscapes to inform value strategy, messaging, and positioning. Regularly analyze market trends, competitive activity, and regulatory landscape to refine Intellia’s approach and enhance the launch trajectory. Assess the impact of key policies to the portfolio (e.g. IRA.)
- Pricing & Reimbursement Strategy: Collaborate with market access and HEOR teams to shape pricing and reimbursement strategies, leveraging a deep understanding of gene therapy valuation models. Develop arguments, evidence frameworks and communication materials to support optimal coverage and reimbursement, particularly for novel therapies in rare disease.
- Cross-Functional Leadership: Lead cross-functional initiatives with internal stakeholders to ensure cohesive launch readiness. Act as a primary point of contact for strategic communications efforts related to product value, bridging scientific, commercial, and patient-oriented teams to create unified messages. Effectively leads cross-functionally, particularly across Market Access, HEOR, Brand, Regulatory, and Medical to ensure alignment around, and delivery against, access goals and ensures access view is represented in commercial and development plans, and forecasts. The access lead plays a key role in aligning and integrating strategic and tactical launch activities within market access across HEOR, pricing & contracting, channel strategy & account management.
- External Engagement & Advocacy: Build strong relationships with external stakeholders, including key opinion leaders, patient advocacy groups, and payers & other reimbursement decision-makers. Represent Intellia at conferences, advisory boards, and other key forums to communicate the value and promise of our therapies.
About You:
- Proven success in leading value strategy, market access, or strategic communications functions in a launch setting, with demonstrated ability to deliver differentiated and compelling value narratives and customer-facing access marketing materials.
- Track record of effectively launching first in class products in the United States, including pre-launch early payer engagement and market development
- Experience in developing provider site and channel access & reimbursement strategy in the US and its implementation to support site readiness for product adoption and administration.
- Deep knowledge of healthcare payer systems, reimbursement models – including the US buy-and-bill model, and value frameworks, especially in rare disease.
- Customer-facing payer or account management experience preferred.
- Strong analytical and strategic thinking skills, with a track record of influencing cross-functional teams and external stakeholders.
- Exceptional written and verbal communication skills, with the ability to simplify complex concepts and present confidently to a range of audiences.
- Ability to work effectively in a fast-paced, growth-oriented environment with a commitment to addressing the unique challenges of gene editing therapies.
- Advanced degree (MBA, PharmD, PhD, MD) or equivalent in business, life sciences, public health, or a related field.
- 10+ years of experience in biopharma, ideally in gene therapy, gene editing, or other innovative therapeutics, with 8+ years in market access and a preference for experience in rare disease and/or cardiovascular.
#LI-Hybrid
#LI-SV1
Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, are expected to follow all applicable federal, state, and local public health regulations and guidelines, and are strongly encouraged to follow all public health recommendations, including being vaccinated for COVID-19.
EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
What We Do
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help.
Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.
View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/